Top-News

Inventiva .(prom.)-,01 News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF
3,27 €
+0,01 €
+0,31%
07.05.24 18:45:19
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

Inventiva .(prom.)-,01 News

08.06.23 - GlobeNewswire
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  
Daix (France), Long Island City (New York, United States) / Paris (France) and Waltham (United States), June 8, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a ...
07.06.23 - GlobeNewswire
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
Five poster presentations showing : the correlation between the improvement of hepatic steatosis and a robust increase in adiponectin levels, improvement in lipid profile and ...
26.05.23 - GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
25.05.23 - GlobeNewswire
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of ...
25.05.23 - GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
Daix, 25 May 2023
16.05.23 - GlobeNewswire
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
Cash and cash equivalents at €56.3 million, short-​term deposits at €0.7 million 2 , and long term deposit at €9.3 million 3 as of March 31, 2023, compared to €86.7 million, €1.0 million ...
04.05.23 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
Article R. 22-10-23 of the French Commercial Code
04.05.23 - GlobeNewswire
Combined General Meeting of May 25, 2023. Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), May 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
30.03.23 - GlobeNewswire
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States) , March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
29.03.23 - GlobeNewswire
Inventiva reports its 2022 full-year results
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, ...
23.03.23 - GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Daix (France), Long Island City (New York, United States) , March 23 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
14.02.23 - GlobeNewswire
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-​stage biopharmaceutical ...
04.01.23 - GlobeNewswire
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the ...
03.01.23 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
Article R. 22-10-23 of the French Commercial Code
03.01.23 - GlobeNewswire
Combined General Meeting of January 25, 2023 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
12.12.22 - GlobeNewswire
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
Inventiva intends to use the proceeds to fund part of the pivotal Phase III clinical trial evaluating lanifibranor in patients with NASH The €25 million supports Inventiva’s anticipated cash ...
28.11.22 - GlobeNewswire
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to ...
21.11.22 - GlobeNewswire
Inventiva announces a new Director of the Board of Directors
Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on ...
10.11.22 - GlobeNewswire
Inventiva reports 2022 Third Quarter Financial Information¹
Cash position 2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022 Revenues of €0.1m for the ...
31.10.22 - GlobeNewswire
Inventiva provides an update on the development of cedirogant by AbbVie
Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...

Newssuche

Videos

newspaper
07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »